PMR

Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Research, SAFE, Growth, HOPE, CE, Patient, PMR, ACTION, UKCA, Hydrocephalus, ECMO, News, MDR, Pediatrics, Malnutrition, Nursing care plan, Marketing, FDA, Video game

Revenues for the fourth quarter of 2023 were $2.69 million, up 89%, compared to $1.42 million in the fourth quarter of 2022.

Key Points: 
  • Revenues for the fourth quarter of 2023 were $2.69 million, up 89%, compared to $1.42 million in the fourth quarter of 2022.
  • Gross margin for the fourth quarter of 2023 was $1.03 million, compared to $0.30 million in the fourth quarter of 2022.
  • Research and development expenses for the fourth quarter of 2023 were $5.96 million, compared to $5.22 million in the fourth quarter of 2022.
  • Sales, marketing, general, and administrative expenses for the fourth quarter of 2023 were $6.70 million, compared to $8.71 million in the fourth quarter of 2022.

Three PMR Attorneys Included on List of Nation’s Top Plaintiff Lawyers

Retrieved on: 
Wednesday, March 13, 2024
Legal, Professional Services, Professional, Thomson Reuters, The National Law Journal, Apple, Lawyer, PMR, LLP, Peer review, AirPods, Huber loss

Paranjpe Mahadass Ruemke LLP, or PMR Law, is pleased to announce that Lawdragon has honored three of the firm’s attorneys in its 500 Leading Plaintiff Consumer Lawyers guide for 2024.

Key Points: 
  • Paranjpe Mahadass Ruemke LLP, or PMR Law, is pleased to announce that Lawdragon has honored three of the firm’s attorneys in its 500 Leading Plaintiff Consumer Lawyers guide for 2024.
  • Both are consistently honored for plaintiffs work by The Best Lawyers in America and Texas Super Lawyers, published by Thomson Reuters.
  • Texas Lawyer magazine has ranked PMR Law among Houston’s best personal injury firms for two consecutive years in its “Best of” listing.
  • PMR Law’s priority is to provide personalized attention, professionalism and tireless representation.

Sonim Set to Seize Market Opportunity Amidst Bullitt Exit

Retrieved on: 
Wednesday, February 21, 2024
SONM, Mobile, SVP, Sonim, Health, GM, Bullitt, ESG, PMR, Agriculture, Online shopping

Sonim presents immediate solution to fill Bullitt void at MWC Barcelona with superior solutions, by appointment only

Key Points: 
  • Chuck Becher, Chief Commercial Officer at Sonim, says: "For nearly two decades, Sonim has been a trusted name in the rugged phone sector, offering solutions that outperform standard consumer phones.
  • Simon Rayne, SVP and GM of EMEA and APAC at Sonim, adds: "Sonim already has a footprint in Europe, and this expansion comes at an opportune time.
  • Sonim's European presence and staffing enable the company to provide prompt solutions to former Bullitt partners, operators, and customers.
  • Schedule a meeting with the Sonim team at the Mobile World Congress in Barcelona, Feb 26-29, in Hall 3, PMR 3B23Ex.

Trinity Life Sciences Launches Brand Insights AI

Retrieved on: 
Wednesday, February 28, 2024
COVID-19, Research, Neurology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, AIML, Multimedia, AI, Code, Investment, Front line, Generative, PPT, Partnership, Intellectual property, PMR, Trinity, Sheraton

Trinity Life Sciences , a leader in global life sciences commercialization solutions, today launched Brand Insights AI to develop, share and refine insights across the full breadth of biopharmaceutical brand research.

Key Points: 
  • Trinity Life Sciences , a leader in global life sciences commercialization solutions, today launched Brand Insights AI to develop, share and refine insights across the full breadth of biopharmaceutical brand research.
  • Brand Insights AI represents the intersection of AI and our biopharma-specific market research expertise, combined to supercharge a brand’s insights.”
    Dr. Deshpande will be speaking on GenAI solution exploration at the upcoming Trinity Life Sciences Forum on AI on April 23, 2024.
  • “Trinity Brand Insights AI is an excellent example of a paradigm-shifting tool for brand and insights teams that uses the latest technology.
  • Brand Insights AI allows brand and insights teams to:
    Trinity is hosting an AI forum, Making AI Real: Lessons From the Frontlines , on April 23, 2024 at the Sheraton Commander Hotel in Cambridge, MA.

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, February 28, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, SRPT, Hart–Scott–Rodino Antitrust Improvements Act, Investment, Interest, Sarepta Therapeutics, Part, Sale, University, Trial of the century, Ageing, BLA, GAAP, Therapy, BioMarin Pharmaceutical, Income tax, PMR, Depreciation, Magnesium deficiency, Nationwide Children's Hospital, Hospital, Safety, Patent, Clinical trial, Biologics license application, Mutation, Priority review, Acquisition, PIN, Dystrophin, FDA, Food, DMD, Duchenne muscular dystrophy, U.S. FDA, Agency, Patient, PRV, PMO, Pharmaceutical industry

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2023.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2023.
  • Beginning in the fourth quarter of 2023, amortization of in-licensed rights (formerly included within depreciation and amortization expense) and income tax (benefit) expense are no longer excluded from the non-GAAP results.
  • Non-GAAP financial results for the fourth quarter and full-year 2022 have been updated to reflect this change for comparability.
  • All relevant non-GAAP measures are reconciled from their respective GAAP measures in the attached table “Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures.”

Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study

Retrieved on: 
Thursday, February 1, 2024
Health, Medical Devices, Neurology, Health Technology, Radiology, Clinical Trials, Cardiology, Abstract, ISC, Massachusetts General Hospital, Hospital, Research, MD, ACTION, Patient, Stroke, Diagnosis, FDA, Hyperfine structure, Doctor of Philosophy, PMR, Conference, Medical imaging

These abstracts demonstrate the depth and breadth of research into the clinical utility and applications of portable ultra-low-field MR imaging.

Key Points: 
  • These abstracts demonstrate the depth and breadth of research into the clinical utility and applications of portable ultra-low-field MR imaging.
  • Conference attendees can learn more during the presentations listed below.
  • Maria Sainz, Hyperfine, Inc. president and CEO, said, “Acute ischemic stroke remains a large and growing global health issue.
  • Evaluating the opportunity for the Swoop® system to contribute to better stroke care remains incredibly compelling for our company.

Seagate’s Breakthrough 30TB+ Hard Drives Ramp Volume, Marking an Inflection Point in the Storage Industry

Retrieved on: 
Wednesday, January 17, 2024
Technology, Telecommunications, Nanotechnology, Audio, Video, Internet, Hardware, Data Management, Artificial Intelligence, VoIP, HAMR, IDC, Physics, Instability, Multimedia, TB, Exos, PMR, Miniaturization, Plasmon, NAS, Carbon, Heat-assisted magnetic recording, Acquisition, VIA, Fundamental, Research, Computer data storage

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    The company launched the Mozaic 3+™ hard drive platform—which incorporates Seagate’s trailblazing implementation of Heat-Assisted Magnetic Recording (HAMR) technology.
  • The Mozaic 3+ platform powers Seagate’s flagship Exos® product family, with newly announced, industry-leading capacity points of 30TB and beyond.
  • Seagate’s areal density innovation—which increases the number of bits that can be stored on a platter—addresses common industry pain points.
  • In Mozaic 3+ hard drives, the media alloy uses a pioneering iron-platinum superlattice structure, which significantly increases the magnetic coercivity of disk media.

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

Retrieved on: 
Tuesday, January 9, 2024
Pancreatic cancer, Research, Biology, Prostate cancer, Cancer, Cytokine release syndrome, CRS, AML, Population Reference Bureau, Audit committee, AMGN, NK, Neoplasm, ADC, Acute myeloid leukemia, Paracetamol, PMR, NKG2D, NSCLC, Disease, Safety, Conditional sentence, Brain, Lung cancer, Breast, PALM, Cytarabine, Senior, Prevalence, Genetics, Nonsteroidal anti-inflammatory drug, Drug discovery, Graft-versus-host disease, Ruxolitinib, TSX, Therapy, Kidney cancer, Ageing, Patient, Stomach, Complete Response Letter, Fentanyl, Breast cancer, Novartis, Society, Eli Lilly, News, Food, Cancer pain, Johnson & Johnson, Morphine, FDA, Ovarian cancer, New Drug Application, ASH, ONC, Pharmaceutical industry

Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.

Key Points: 
  • Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.
  • The entire medical research fraternity has prioritized cancer research in order to find new ways of treatment and analysis.
  • According to Nova one advisor, the global Oncology Cancer Drugs market was valued at USD 147.2 billion in 2021 and it is expected to hit around USD 289.2 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030.
  • The article continued: “Drugs such as morphine, fentanyl, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and others are used extensively in treating cancer pain in patients with lung cancer, bone cancer, and other types of cancer.

LBank Exchange Amplifies Web3 Gaming Integration with Pomerium (PMG) on December 11, 2023

Retrieved on: 
Monday, December 11, 2023
Blockchain, Ecosystem, PMG, Non-fungible token, IP, PMR, Web 2.0, PC, Creativity, Video game

Pomerium (PMG), a Blockchain Web3 game onboarding platform, aims to bridge the Web2 and Web3 gaming gap by creating original content and games featuring Pomeranian-based characters.

Key Points: 
  • Pomerium (PMG), a Blockchain Web3 game onboarding platform, aims to bridge the Web2 and Web3 gaming gap by creating original content and games featuring Pomeranian-based characters.
  • LBank Exchange is thrilled to announce the upcoming listing of Pomerium (PMG), an innovative Web3 game studio, revolutionizing the gaming industry by blending traditional Web2 games with the advanced technology of Web3.
  • By harmonizing Web2 and Web3 gaming platforms, Pomerium not only caters to the current trends in the gaming market but also sets the stage for future innovations.
  • This blend of technology, creativity, and strategic market insight makes Pomerium a unique and forward-thinking entity in the gaming world.

Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status

Retrieved on: 
Friday, December 22, 2023
FDA, Health, Research, Pharmaceutical, Science, Biotechnology, Patient, Food, Agency, Priority review, Physician, Roche, Duchenne muscular dystrophy, Disease, Sarepta Therapeutics, Biologics license application, Therapy, SRPT, Mutation, PMR, DMD, BLA, Pharmaceutical industry

The supplement was submitted to the U.S. Food and Drug Administration (FDA) with a request for Priority Review.

Key Points: 
  • The supplement was submitted to the U.S. Food and Drug Administration (FDA) with a request for Priority Review.
  • An efficacy supplement is a submitted request for a proposed change to an approved product’s labeling, including adding or modifying an indication previously filed with the FDA.
  • Sarepta has also completed the EMBARK postmarketing requirement (PMR) and submitted the PMR to FDA requesting conversion from accelerated approval to traditional approval.
  • Roche is responsible for regulatory approvals and bringing ELEVIDYS to patients across the rest of the world.